NASDAQ: SABS
Sab Biotherapeutics Inc Stock Ownership - Who owns Sab Biotherapeutics?

Insider buying vs selling

Have Sab Biotherapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Andrew MoinDirector2025-09-291,740,000$1.75
$3.05MBuy
Sessa Capital Master LPDirector2025-09-291,740,000$1.75
$3.05MBuy

1 of 1

SABS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SABS insiders and whales buy or sell their stock.

SABS Shareholders

What type of owners hold Sab Biotherapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Vivo Capital LLC14.94%11,420,000$43.28MInstitution
Christine E. Hamilton14.70%11,237,694$42.59MInsider
Edward D. Hamilton13.11%10,023,848$37.99MInsider
Caligan Partners LP10.42%7,967,207$30.20MInstitution
Andrew Moin8.87%6,783,028$25.71MInsider
Perceptive Advisors LLC8.41%6,431,743$24.38MInstitution
Ilan Katz7.97%6,097,150$23.11MInsider
Eddie Joe Sullivan6.84%5,232,304$19.83MInsider
Commodore Capital LP5.76%4,401,500$16.68MInstitution
Ra Capital Management LP5.76%4,401,500$16.68MInstitution

1 of 3

SABS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SABS57.16%42.84%Net Buying
NMRA30.07%69.93%Net Buying
AVXL43.15%4.79%Net Buying
OABI38.59%23.01%Net Buying
FULC62.71%37.29%Net SellingNet Buying

Sab Biotherapeutics Stock Ownership FAQ

Who owns Sab Biotherapeutics?

Sab Biotherapeutics (NASDAQ: SABS) is owned by 90.49% institutional shareholders, 67.81% Sab Biotherapeutics insiders, and 0.00% retail investors. Christine E. Hamilton is the largest individual Sab Biotherapeutics shareholder, owning 11.24M shares representing 14.70% of the company. Christine E. Hamilton's Sab Biotherapeutics shares are currently valued at $43.27M.

If you're new to stock investing, here's how to buy Sab Biotherapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.